index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

98

 

NOTICES

156

 

 

MOTS CLES

Biologic drug Sipuleucel-T Autoimmune diseases Apremilast Adolescent Pharmacoepidemiology Sacroiliitis Ustekinumab Biological Therapy Alitretinoin Access to care Vigibase® Antimicrobial Stewardship Adverse side effects Biosimilar Pharmaceuticals COVID-19 Biologic therapy Aging Immunotherapy Cardio-oncology BTK protein Bacterial rhinosinusitis Biological therapy ASDAS Autoimmunity Dermatology Pharmaco-Épidémiologie Atrial fibrillation Antibiotic misuse Pharmacovigilance Atopic dermatitis Immune checkpoint inhibitors Acute Myeloid Leukaemia AML Immune-related adverse events Glucocorticoids Amyloidosis Arthritis Abus d'antibiotiques Accelerometer Antimicrobiens Systematic review Addiction Ankylosing Anxiety Anti-HCV Direct Acting Antivirals DAA Anti-TNF Placebo Angiotensin receptor blockers ArtThese Azathioprine Antibiotics Quality of life Apre-milast Anxiété Auto-Diagnostic Primary adrenal insufficiency Epidemiology Network meta-analysis Ethics Auto-immune hepatitis Alcohol Cardiotoxicity Arrhythmia Intensive care Burden Albinism Axial spondyloarthritis Bacterial Spondylitis Anti-Bacterial Agents Psoriatic arthritis Cancer Antimicrobial resistance Biologic Management Etanercept Angiotensin-converting enzyme inhibitors Graft-versus-host disease Antibiotic resistance Biomédicaments Treatment Meta-Analysis Pregnancy Psoriasis Drug reaction Infliximab Spondyloarthritis Ankylosing spondylitis Biomarkers Beta-lactam antibiotics Biologics Anticancer drugs Antimicrobials Endocrine toxicity Méta-Analyse Prostate cancer Cardiomyopathy Drug survival Stability Adalimumab

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS